News 23 Mar 2023 New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients admin
News 23 Mar 2023 Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients admin
News 03 Mar 2023 Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders admin
News 02 Mar 2023 Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022 admin
News 01 Mar 2023 Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update admin
News 19 Jan 2023 Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member admin
News 13 Jan 2023 Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress admin
News 03 Jan 2023 Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure admin
News 17 Nov 2022 Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option admin
